blinatumomab,inotuzumab
pfizer,amgen,ucb pharmaceuticals,astellas
['bet', 'leusm', 'blinatumomab', 'inotuzumab']
#ash22 #leusm stelljes: 100% cr/cri with ino induction alone, 74% mrd neg after c3 ino. efs at 1yr 88%, at 2yr 73%. os 81% at 2yr. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)